Literature DB >> 31919279

Structural insight into T cell coinhibition by PD-1H (VISTA).

Benjamin T Slater1, Xue Han1, Lieping Chen2, Yong Xiong3.   

Abstract

Programmed death-1 homolog (PD-1H), a CD28/B7 family molecule, coinhibits T cell activation and is an attractive immunotherapeutic target for cancer and inflammatory diseases. The molecular basis of its function, however, is unknown. Bioinformatic analyses indicated that PD-1H has a very long Ig variable region (IgV)-like domain and extraordinarily high histidine content, suggesting that unique structural features may contribute to coinhibitory mechanisms. Here we present the 1.9-Å crystal structure of the human PD-1H extracellular domain. It reveals an elongated CC' loop and a striking concentration of histidine residues, located in the complementarity-determining region-like proximal half of the molecule. We show that surface-exposed histidine clusters are essential for robust inhibition of T cell activation. PD-1H exhibits a noncanonical IgV-like topology including an extra "H" β-strand and "clamping" disulfide, absent in known IgV-like structures, that likely restricts its orientation on the cell surface differently from other IgV-like domains. These results provide important insight into a molecular basis of T cell coinhibition by PD-1H.

Entities:  

Keywords:  PD-1H; T cell coinhibition; VISTA; cancer immunotherapy; structure

Mesh:

Substances:

Year:  2020        PMID: 31919279      PMCID: PMC6983362          DOI: 10.1073/pnas.1908711117

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  50 in total

1.  Crystal structure of a soluble CD28-Fab complex.

Authors:  Edward J Evans; Robert M Esnouf; Raquel Manso-Sancho; Robert J C Gilbert; John R James; Chao Yu; Janet A Fennelly; Cheryl Vowles; Thomas Hanke; Björn Walse; Thomas Hünig; Poul Sørensen; David I Stuart; Simon J Davis
Journal:  Nat Immunol       Date:  2005-02-06       Impact factor: 25.606

2.  Structures of T cell immunoglobulin mucin protein 4 show a metal-Ion-dependent ligand binding site where phosphatidylserine binds.

Authors:  César Santiago; Angela Ballesteros; Laura Martínez-Muñoz; Mario Mellado; Gerardo G Kaplan; Gordon J Freeman; José M Casasnovas
Journal:  Immunity       Date:  2007-12       Impact factor: 31.745

3.  VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer.

Authors:  Jianjun Gao; John F Ward; Curtis A Pettaway; Lewis Z Shi; Sumit K Subudhi; Luis M Vence; Hao Zhao; Jianfeng Chen; Hong Chen; Eleni Efstathiou; Patricia Troncoso; James P Allison; Christopher J Logothetis; Ignacio I Wistuba; Manuel A Sepulveda; Jingjing Sun; Jennifer Wargo; Jorge Blando; Padmanee Sharma
Journal:  Nat Med       Date:  2017-03-27       Impact factor: 53.440

4.  Evolution of the B7 family: co-evolution of B7H6 and NKp30, identification of a new B7 family member, B7H7, and of B7's historical relationship with the MHC.

Authors:  Martin F Flajnik; Tereza Tlapakova; Michael F Criscitiello; Vladimir Krylov; Yuko Ohta
Journal:  Immunogenetics       Date:  2012-04-11       Impact factor: 2.846

5.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

Review 6.  Molecular mechanisms of T cell co-stimulation and co-inhibition.

Authors:  Lieping Chen; Dallas B Flies
Journal:  Nat Rev Immunol       Date:  2013-03-08       Impact factor: 53.106

7.  Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig.

Authors:  Joel M Kremer; Rene Westhovens; Marc Leon; Eduardo Di Giorgio; Rieke Alten; Serge Steinfeld; Anthony Russell; Maxime Dougados; Paul Emery; Isaac F Nuamah; G Rhys Williams; Jean-Claude Becker; David T Hagerty; Larry W Moreland
Journal:  N Engl J Med       Date:  2003-11-13       Impact factor: 91.245

8.  Blocking the VISTA pathway enhances disease progression in (NZB × NZW) F1 female mice.

Authors:  P A Sergent; S F Plummer; J Pettus; R Mabaera; J K DeLong; D A Pechenick; C M Burns; R J Noelle; S Ceeraz
Journal:  Lupus       Date:  2017-06-28       Impact factor: 2.911

9.  UniProt: a worldwide hub of protein knowledge.

Authors: 
Journal:  Nucleic Acids Res       Date:  2019-01-08       Impact factor: 16.971

10.  Initiation of T cell signaling by CD45 segregation at 'close contacts'.

Authors:  Veronica T Chang; Ricardo A Fernandes; Kristina A Ganzinger; Steven F Lee; Christian Siebold; James McColl; Peter Jönsson; Matthieu Palayret; Karl Harlos; Charlotte H Coles; E Yvonne Jones; Yuan Lui; Elizabeth Huang; Robert J C Gilbert; David Klenerman; A Radu Aricescu; Simon J Davis
Journal:  Nat Immunol       Date:  2016-03-21       Impact factor: 25.606

View more
  9 in total

Review 1.  IGSF11 and VISTA: a pair of promising immune checkpoints in tumor immunotherapy.

Authors:  Xi-Yang Tang; Yan-Lu Xiong; Xian-Gui Shi; Ya-Bo Zhao; An-Ping Shi; Kai-Fu Zheng; Yu-Jian Liu; Tao Jiang; Nan Ma; Jin-Bo Zhao
Journal:  Biomark Res       Date:  2022-07-13

Review 2.  VISTA inhibitors in cancer immunotherapy: a short perspective on recent progresses.

Authors:  Chenyang Wu; Xin Cao; Xiaojin Zhang
Journal:  RSC Med Chem       Date:  2021-07-06

3.  A small molecule inhibitor of VSIG-8 prevents its binding to VISTA.

Authors:  Wenting Chen; Chenxin Qie; Xinlei Hu; Lanlan Wang; Jingwei Jiang; Wanmei Liu; Jun Liu
Journal:  Invest New Drugs       Date:  2022-04-11       Impact factor: 3.651

4.  Molecular Markers for Long-term Survival in Stage IIIA (N2) NSCLC Patients.

Authors:  Anca Nastase; Simona O Dima; Audrey Lupo; Victoria Laszlo; Rebecca Tagett; Sorin Draghici; Monica Elia Georgescu; Alexandru Nechifor; Sorin Berbece; Irinel Popescu; Marco Alifano; Walter Klepetko; Madalina Grigoroiu
Journal:  Cancer Genomics Proteomics       Date:  2022 Jan-Feb       Impact factor: 4.069

Review 5.  VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy.

Authors:  Long Yuan; Jahnavi Tatineni; Kathleen M Mahoney; Gordon J Freeman
Journal:  Trends Immunol       Date:  2021-01-23       Impact factor: 16.687

Review 6.  Terminating Cancer by Blocking VISTA as a Novel Immunotherapy: Hasta la vista, baby.

Authors:  Ji-Eun Irene Yum; Young-Kwon Hong
Journal:  Front Oncol       Date:  2021-04-16       Impact factor: 6.244

7.  Ablation of T cell-associated PD-1H enhances functionality and promotes adoptive immunotherapy.

Authors:  Li Hu; Ling Chen; Zexiu Xiao; Xu Zheng; Yuangui Chen; Na Xian; Christina Cho; Liqun Luo; Gangxiong Huang; Lieping Chen
Journal:  JCI Insight       Date:  2022-01-25

Review 8.  The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead.

Authors:  Negar Hosseinkhani; Afshin Derakhshani; Mahdi Abdoli Shadbad; Antonella Argentiero; Vito Racanelli; Tohid Kazemi; Ahad Mokhtarzadeh; Oronzo Brunetti; Nicola Silvestris; Behzad Baradaran
Journal:  Front Immunol       Date:  2021-05-19       Impact factor: 7.561

Review 9.  Immunotherapy for Triple-Negative Breast Cancer.

Authors:  Yifeng Cao; Chuyang Chen; Yi Tao; Weifeng Lin; Ping Wang
Journal:  Pharmaceutics       Date:  2021-11-25       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.